BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 589556)

  • 1. A phase I study of pyrazofurin.
    Salem PA; Bodey GP; Burgess MA; Murphy WK; Freireich EJ
    Cancer; 1977 Dec; 40(6):2806-9. PubMed ID: 589556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial clinical study with pyrazofurin.
    Ohnuma T; Holland JF
    Cancer Treat Rep; 1977; 61(3):389-94. PubMed ID: 872139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of marcellomycin with a weekly dose schedule.
    Joss RA; Kaplan S; Goldhirsch A; Varini M; Brunner KW; Cavalli F
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):455-9. PubMed ID: 6683183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of weekly pyrazofurin.
    Cummings FJ; Stoller RG; Calabresi P
    Cancer Treat Rep; 1979 Aug; 63(8):1363-5. PubMed ID: 157807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of pyrazofurin, alone and in combination with trifluorothymidine, in non-Hodgkin's lymphoma.
    Warrell RP; Currie V; Kempin S; Young C
    Cancer Treat Rep; 1979 Aug; 63(8):1423-5. PubMed ID: 113097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical phase I trial of marcellomycin with a single-dose schedule.
    Nicaise C; Rozencweig M; de Marneffe M; Crespeigne N; Dodion P; Piccart M; Sculier JP; Lenaz L; Kenis Y
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):449-54. PubMed ID: 6683182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
    Vogler WR; Trulock PD
    Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study.
    Maroun JA; Fields AL; Pater JL; Stewart DJ; Cripps C; Eisenhauer E
    Cancer Treat Rep; 1984 Sep; 68(9):1121-3. PubMed ID: 6478451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
    Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of aziridinylbenzoquinone (NSC 182986).
    Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
    Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical trial of aclacinomycin A administered on a five-consecutive-day schedule.
    Woolley PV; Ayoob MJ; Levenson SM; Smith FP
    J Clin Pharmacol; 1982; 22(8-9):359-65. PubMed ID: 6957420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial clinical studies with bruceantin.
    Bedikian AY; Valdivieso M; Bodey GP; Murphy WK; Freireich EJ
    Cancer Treat Rep; 1979; 63(11-12):1843-7. PubMed ID: 526918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
    Meguro S; Nagata T; Yokoyama K; Chinen T; Kobayashi T; Yamazaki H; Kuraishi Y; Ichiba ; Abe M; Isogai Y
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1818-22. PubMed ID: 6476844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of L-alanosine (NSC 15353).
    Goldsmith MA; Ohnuma T; Spigelman M; Greenspan EM; Holland JF
    Cancer; 1983 Feb; 51(3):378-80. PubMed ID: 6821823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I and pharmacokinetic study of SM-5887 by 5-day schedule].
    Inoue K; Matsumura A; Horikoshi N; Aiba K; Mukaiyama T; Matsumura T; Ogihara A; Sumida T; Ogawa M
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):477-82. PubMed ID: 1558397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The variability of individual tolerance to methotrexate in cancer patients.
    Hansen HH; Selawry OS; Holland JF; McCall CB
    Br J Cancer; 1971 Jun; 25(2):298-305. PubMed ID: 4256007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.